Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Fig. 3

Effect of premedication on the [177Lu]Lu-PP-F11N uptake in patient 4. Axial CT, SPECT/CT and MIP of [177Lu]Lu-PP-F11N SPECT/CT (A–C) and [68Ga]Ga-DOTATOC PET/CT (D–F) of patient 4. Uptake of [177Lu]Lu-PP-F11N (arrows, with Entresto® premedication) and [68Ga]Ga-DOTATOC (arrowheads) in the predominantly necrotic lymph node metastasis with only low intensity

Back to article page